One Virus, One Bacterium, One Parasite: Different Pathogens, Same Aftermath
In 1999, a research group in Dubbo, Australia, enrolled 253 people at the time of acute infection with one of three pathogens: Epstein-Barr virus (EBV), Coxiella burnetii (the bacterium that causes Q fever), or Ross River virus (a mosquito-borne alphavirus). These three organisms are taxonomically unrelated. They infect different tissues, use different replication strategies, and trigger different arms of the immune system. The researchers followed the patients for months.
At six months, 12% of the cohort had developed a post-infectious fatigue syndrome meeting criteria for chronic fatigue. The rate was the same regardless of which pathogen had caused the acute illness. The severity of the initial infection predicted who would develop chronic fatigue. The identity of the pathogen did not (Hickie et al. 2006).
This finding should have been front-page news in every medical journal. It wasn’t, because it didn’t fit the reigning paradigm — that chronic fatigue syndromes are caused by specific persistent infections, and that the task of research is to find which pathogen is responsible.
The Dubbo data said something different. The pathogen doesn’t matter. The host response does.
1 The list gets longer
In the two decades since Dubbo, the same pattern has been documented after a distressingly wide range of infections.
Epstein-Barr virus: the original “post-viral fatigue” pathogen. Primary EBV infection (mononucleosis/glandular fever) is followed by a chronic fatigue syndrome in approximately 10-12% of cases, with symptoms persisting at six months and beyond (Katz et al. 2009; White et al. 2001).
SARS-CoV-2: the pathogen that proved the pattern at scale. Long COVID affects an estimated 10-20% of infected individuals — tens of millions worldwide — with a symptom profile that overlaps substantially with ME/CFS: post-exertional malaise, cognitive dysfunction, autonomic instability, unrefreshing sleep (Davis et al. 2023). For the first time, the medical system was forced to confront post-infectious fatigue as a mass event rather than an individual curiosity.
Q fever: the Dubbo pathogen that proved the point most cleanly. Q fever fatigue syndrome is recognised as a distinct entity, developing in 20% of acute Q fever cases, with fatigue, myalgia, night sweats, and mood disturbance persisting for years (Marmion et al. 2005).
Ross River virus: post-Ross River fatigue lasts months to years and presents with joint pain, fatigue, and cognitive complaints indistinguishable from ME/CFS (Harley, Sleigh, and Ritchie 2002).
Chikungunya and dengue: both associated with prolonged post-infectious fatigue and chronic arthralgia that persists long after viral clearance (Gerardin et al. 2011; Garcia et al. 2011).
Giardia: the Dubbo group later showed that even a parasitic infection — taxonomically remote from viruses and bacteria — produces post-infectious fatigue in a subset of infected individuals (Naess et al. 2012). The Bergen outbreak of waterborne giardiasis was followed by a documented increase in chronic fatigue cases.
Influenza, SARS, MERS: historical outbreaks each left a trail of chronic fatigue cases in their wake, though without the prospective documentation that Dubbo and Long COVID provided.
The list is a roster of everything that can cause significant acute illness. The organisms share nothing — not taxonomy, not tissue tropism, not replication mechanism. What they share is the ability to trigger a severe immune response.
2 What the convergence means
If the pathogen were the cause, each infection would produce a different chronic syndrome with a different mechanism. Post-EBV fatigue would differ from post-Q-fever fatigue would differ from post-giardia fatigue. They don’t. The syndromes are clinically indistinguishable once established.
If the pathogen were the cause, the rate of chronic fatigue would correlate with pathogen-specific features — viral load, tissue tropism, persistence capacity. It doesn’t. The rate correlates with severity of the acute illness and, to a lesser extent, with host factors like female sex and pre-existing immune gene variants.
If the pathogen were the cause, clearing the pathogen would cure the fatigue. It doesn’t. Post-treatment Lyme disease syndrome persists after Borrelia is eradicated. Long COVID persists after SARS-CoV-2 is cleared. Q fever fatigue persists long after Coxiella is undetectable.
The convergence across radically different pathogens forces a conclusion: ME/CFS (and the post-infectious fatigue syndromes that meet its criteria) is not a chronic infection disease. It is a host-response disease. The pathogen is the trigger. The illness is what the immune system does after the trigger is gone.
3 The host response that fails to switch off
A normal immune response to infection follows a trajectory: detection, alarm, mobilisation, combat, resolution, memory. Each phase transitions to the next. The resolution phase is as actively regulated as the combat phase — it requires specific anti-inflammatory cytokines (IL-10, TGF-β), regulatory T cells, and the clearance of danger-associated molecular patterns (DAMPs) that drove the initial alarm.
The working model for post-infectious ME/CFS is that this resolution fails. The combat phase transitions not to resolution but to a chronic, self-sustaining state of immune activation. Several mechanisms have been proposed, and they are not mutually exclusive:
Molecular mimicry and autoantibody formation. The acute immune response generates antibodies against pathogen proteins. Some of these antibodies cross-react with host proteins — particularly G-protein-coupled receptors that regulate autonomic function and vasculature (Bynke et al. 2020). Once formed, these autoantibodies persist independent of the pathogen and continue driving dysfunction.
Persistent DAMPs. Tissue damage from the acute infection leaves behind debris — mitochondrial DNA, extracellular ATP, nuclear proteins — that the innate immune system interprets as ongoing danger signals. Even after the pathogen is gone, these endogenous danger signals keep the immune system in combat mode.
Epigenetic imprinting. Severe infection alters the epigenetic programming of immune cells — DNA methylation patterns, histone modifications — in ways that persist after the infection resolves. The immune system “remembers” the infection not through adaptive immunity (antibodies and memory T cells, which is normal) but through innate immune reprogramming (trained immunity), which locks inflammatory gene expression into an upregulated state (Netea et al. 2020).
Exhausted T cells. Chronic antigen exposure during the acute phase can drive T cell exhaustion — a state where T cells express inhibitory receptors (PD-1, CTLA-4, LAG-3) and lose their ability to mount effective responses. This leaves latent viruses (EBV, HHV-6, CMV) that healthy immune systems keep suppressed to reactivate, creating a secondary source of chronic immune activation that was not part of the original infection at all.
4 Why this reframes treatment
If ME/CFS were a chronic infection, the treatment would be to find and eliminate the pathogen. Decades of antiviral and antibiotic trials in ME/CFS have produced, at best, modest and inconsistent results — consistent with a model where the pathogen is gone but the damage remains.
If ME/CFS is a host-response disease, the treatment target shifts to the stuck immune state itself:
- Immune modulation: low-dose naltrexone, which modulates microglial activation; IVIg, which resets autoantibody profiles; rituximab, which depletes B cells (including those producing pathogenic autoantibodies)
- Autoantibody removal: immunoadsorption, which physically removes IgG from circulation — trials in ME/CFS are underway with preliminary positive results
- Anti-inflammatory approaches: targeting the specific cytokines and pathways that remain upregulated (JAK inhibitors, IL-6 blockade)
- Resolving the DAMP signal: reducing mitochondrial damage (which produces the DAMPs that sustain immune activation), restoring glymphatic clearance (which removes them from the brain)
None of these approaches target a specific pathogen. All of them target the host machinery that is stuck in the wrong state.
5 What the convergence teaches
The cross-pathogen convergence is one of the most important findings in ME/CFS research, and it is also one of the most underappreciated. It tells us:
Stop looking for the one pathogen. There is no single causative organism. There are dozens of trigger-capable organisms, and the list will keep growing. The convergence of outcomes from divergent triggers means the disease mechanism is downstream of the trigger.
Study the transition. The critical event is not the infection — it is the transition from acute illness to chronic immune dysfunction. Prospective studies that capture this transition in real time (as Dubbo did, and as Long COVID studies are doing at scale) are worth more than a thousand retrospective surveys of established patients.
Treat the state, not the history. A patient who developed ME/CFS after EBV and a patient who developed it after surgery are, once the disease is established, the same patient. They have the same stuck immune state, the same metabolic consequences, the same treatment targets. Their entry points differ. Their current disease does not.
Take all post-infectious fatigue seriously. If 10-12% of significant acute infections lead to chronic fatigue syndromes, the global burden is staggering — and most of it is invisible because medicine doesn’t recognise the pattern. Every acute infection is a potential ME/CFS trigger. Post-infectious follow-up should be standard, not incidental.
COVID proved this at a scale that couldn’t be ignored. The question is whether medicine will recognise that the pattern was always there, for every pathogen, or whether it will treat Long COVID as a special case and let the other 90% of post-infectious ME/CFS patients remain invisible.